Chimeric Antigen Receptor-T (CAR-T) Cell Therapy Targeting BCMA in Patients with Prior Allogeneic Transplantation (Allo-Hct) in Relapsed And/or Refractory Multiple Myeloma (RRMM)

Lindsay Hammons,Shabi Haider,Andrew J. Portuguese,Rahul Banerjee,Aniko Szabo,Marcelo Pasquini,Saurabh Chhabra,Sabarinath Radhakrishnan,Meera Mohan,Ravi Narra,Jing Dong,Siegfried Janz,Nirav N. Shah,Mehdi Hamadani,Anita D'Souza,Parameswaran Hari,Binod Dhakal
DOI: https://doi.org/10.1182/blood-2022-165483
2023-01-01
British Journal of Haematology
Abstract:SummaryChimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific T‐cell engagers (BsAb) have emerged as promising immunotherapeutic modalities in patients with relapsed and/or refractory multiple myeloma (RRMM). However, there is limited data on the safety and efficacy of CAR‐T and BsAb therapies in MM patients with a prior history of allogeneic transplantation (allo‐HCT). Thirty‐three MM patients with prior allo‐HCT received CAR‐T (n = 24) or BsAb (n = 9) therapy. CAR‐T therapy demonstrated an ORR of 92% (67% ≥ CR), and 73% were MRD negative. BsAb therapy resulted in an ORR of 44% (44% ≥ CR) and 44% MRD negative. Safety analysis showed grade ≥3 AEs in 92% of CAR‐T and 56% of BsAb patients. Cytokine release syndrome (CRS) occurred in 83% of CAR‐T and 78% of BsAb recipients, while immune effector cell‐associated neurotoxicity syndrome (ICANS) was observed in three CAR‐T patients. Infections of grade ≥3 were reported in 50% of CAR‐T and 44% of BsAb recipients. No exacerbation of graft‐versus‐host disease occurred except in one BsAb recipient. CAR‐T and BsAb therapies appear to be feasible, safe and provide deep and durable responses in MM patients with prior allo‐HCT.
What problem does this paper attempt to address?